Functional Respiratory Imaging (FRI) to assess the short-term effect of the product ORKAMBI (lumacaftor/ ivacaftor) on lung function in ORKAMBI-naive patients with Cystic Fibrosis Homozygous for Phe508del.
Phase of Trial: Phase IV
Latest Information Update: 24 Aug 2018
At a glance
- Drugs Ivacaftor/lumacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- 24 Aug 2018 Planned End Date changed to 11 Jun 2019.
- 21 Aug 2018 Status changed from not stated to recruiting.
- 06 Jun 2018 New trial record